What is your approach to maintenance therapy post autologous stem cell transplant for patients with concurrent multiple myeloma and AL amyloidosis?
Does your choice of agent differ, or are you more or less likely to offer maintenance than if the patient had multiple myeloma alone?
2 Answers
Mednet MemberInvited Expert
Medical Oncology · OhioHealth
Answered on
The short answer is, I give maintenance for the multiple myeloma (MM) just as I would for patients with pure MM. While there is no data yet for maintenance in AL amyloid (hopefully soon, and many physicians do use maintenance in AL amyloid in patients with >=10% plasma cells at diagnosis), do not di...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · University of Kansas Medical Center
Answered on
If the patient has a confirmed diagnosis of multiple myeloma and AL amyloidosis, I will consider using a PI/bortezomib as maintenance therapy regardless of the type of response. If the patient has MGUS with AL amyloidosis, I will evaluate the hematological and organ response. If the patient achieved...
Join for free or sign in to see the full answer